Company intelligence / Profile preview

Artegraft

North Brunswick, New Jersey, United Stateslemaitre.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

The Artegraft bovine carotid artery vascular graft has been commercially available for use primarily in hemodialysis access patients. It features a biological fibrous matrix processed to enhance long-term patency and flexibility. The product has demonstrated commercial success with $15.6 million in trade sales over a recent twelve-month period prior to acquisition by LeMaitre Vascular. No specific clinical trial results are detailed in the provided sources.

Therapeutic areas: NephrologyCardiovascular
Modalities: Biologic (bovine-derived vascular graft)Device (vascular graft/implant)
Industry: Implantable Medical Devices

Partnerships

KeyBank National Association and Truist Bank provided credit facility for acquisition financingSVB Leerink acted as financial advisor during acquisition

Beyond the preview

Go deeper on Artegraft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artegraft.

Explore the full profile